ABSTRACT BACKGROUND In patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), studies have
METHODS
PATIENT POPULATION. The population for this study was derived from the TVT Registry, a national registry (16) designed to track outcomes of TAVR and other therapies for valvular heart disease. Data are collected using standardized definitions for clinical and procedural details and outcomes as previously described (16) The analytic cohort was stratified according to LVEF and AVG. First, the cohort was divided into 3 groups according to LVEF using clinically relevant cutpoints:
severe LV dysfunction (LVEF <30%); mild/moderate LV dysfunction (LVEF 30% to 50%); and preserved LV function (LVEF >50%). Next, the cohort was divided into 2 groups according to mean AVG as assessed by preprocedure echocardiography: low AVG (mean AVG <40 mm Hg) and high AVG (mean AVG $40 mm Hg). Of note, the TVT Registry does not currently distinguish whether the AVG is derived from a resting or stress echocardiogram. Furthermore, the assessment of stroke volume index (SVI) was not feasible because of the inability to reliably calculate flow based on available data elements in the TVT Registry.
STUDY OUTCOMES. For clinical endpoints, outcomes were evaluated at hospital discharge and at 1 year using the TVT Registry data and Medicare claims data, respectively. In-hospital outcomes included death, myocardial infarction (MI), stroke, new requirement for dialysis, and length of hospital stay.
Clinical outcomes at 1 year included death, MI, stroke, and hospitalization for recurrent heart failure. Medicare claims files were used for detection of rehospi- Baron et al.
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severe AS (17 Mortality rates are summarized using Kaplan-Meier estimates and were compared using Cox proportional hazards models. For stroke, MI, and recurrent heart failure, the cumulative incidence function was used to estimate the probability of each event occurring over the first year of follow-up, with death as a competing event. For each endpoint, the cumulative incidence at 1 year was estimated nonparametrically using the Fine and Gray method (21).
Adjusted analyses were also performed to examine the independent association between both AVG and and AVG and mortality. For stroke, MI, and recurrent heart failure, differences in the adjusted incidence of these events were assessed based on hazard ratios from a Fine and Gray proportional subdistributions hazards model, with death as a competing event (21).
For each model, in addition to the main effects and the covariates listed previously, interaction terms for AVG and LVEF were also evaluated. All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, North Carolina). were significantly higher in patients with low AVG (7.6% vs. 6.9%; p < 0.001).
RESULTS

IN-HOSPITAL
OUTCOMES. In-hospital outcomes stratified by LVEF and AVG are summarized in Tables 3 and 4 , respectively. In unadjusted analyses, LV dysfunction was associated with increased length of stay (median: 7 vs. 7 vs. 6 days; p < 0.001) and a trend toward higher mortality (6.4% vs. 5.4% vs. 4.7%; p ¼ 0.069). Patients with low AVG also tended to have worse in-hospital outcomes including higher rates of mortality (5.6% vs. 4.7%, p ¼ 0.035) and longer length of stay (7 vs. 6 days, p < 0.001).
1-YEAR CLINICAL OUTCOMES.
Severe LV dysfunction was associated with higher rates of mortality (29.3% vs. 25.5% vs. 21.9%, p < 0.001) and of recurrent heart failure (19.3% vs. 17.2% vs. 12.8%, p < 0.001) at 1 year (Figures 2A and 2B, respectively) .
Similarly, patients with low AVG had higher rates of 1-year mortality (27.1% vs. 21.5%, p < 0.001) and of hospitalization for heart failure (19.2% vs. 11.9%, p < 0.001) when compared with patients with high AVG ( Figures 3A and 3B, respectively) . There was no association between baseline LVEF or AVG and 1-year rates of either stroke or MI.
When the study cohort was stratified simultaneously by both LV function and AVG, rates of 1-year mortality and heart failure were higher for patients Baron et al. (Table 5) ; however, the absolute change in KCCQ-OS scores was greatest for patients with severe LV dysfunction and least for patients with normal LV function at baseline (32.8 vs. 28.1 vs. 24.0 points, respectively; p < 0.001).
Patients with severe LV dysfunction were most likely to experience a substantial health status improvement (56.9% vs. 52.3% vs. 48.2%; p < 0.001), and these differences persisted in risk-adjusted analyses.
In contrast, there were no significant differences between the low and high AVG group for any of the 30-day health status outcomes. After controlling for baseline factors (Table 6) , low AVG was associated with a marginally smaller improvement in the KCCQ-OS score (mean adjusted difference: -1.7 points; p ¼ 0.018). There was no evidence of effect modification with respect to LV dysfunction or AVG on any health status outcomes (all p values for interaction were nonsignificant).
DISCUSSION
In this large study of a real-world population undergoing commercial TAVR implantation, we found that Values are median (25th-75th percentile) or %.
AVG ¼ aortic valve gradient; other abbreviations as in Table 1 . Values are n (%) or median (interquartile range). *Among patients discharged alive.
LVEF ¼ left ventricular ejection fraction. Values are n (%) or median (interquartile range). *Among patients discharged alive.
AVG ¼ aortic valve gradient. 
Mortality
Recurrent Heart Failure A B Kaplan-Meier curves depicting all-cause mortality (A) and recurrent heart failure hospitalization (B) over the first year of follow-up after TAVR, stratified by LVEF.
Abbreviations as in Figure 1 .
Our finding that low AVG, but not reduced LVEF, was associated with increased long-term mortality after TAVR likely reflects that low AVG may be an indication of reduced flow, which is often related to intrinsic myocyte dysfunction. In fact, in some studies, low SVI has been shown to be a more powerful independent predictor of post-TAVR mortality than either EF or AVG (14) . Previous studies have demonstrated that patients with low-flow, lowgradient AS have evidence of myocardial fibrosis A B
Kaplan-Meier curves depicting all-cause mortality (A) and recurrent heart failure hospitalization (B) over the first year of follow-up after TAVR. Abbreviations as in Figure 1 . Values are median (interquartile range) or n (%). *Change from baseline KCCQ-OS >20 points. †Refers to absolute change in KCCQ-OS (per 10% point reduction in LVEF). ‡Adjusted odds ratio (per 10% point reduction in LVEF).
patients with better health status may be more likely to complete the KCCQ questionnaire. Consequently, the generalizability of our findings on health status outcomes to the overall TAVR population is uncertain. Third, because follow-up outcomes were derived from administrative claims data, it is possible that some hospitalizations for heart failure were missed because of miscoding. Fourth, echocardiographic and hemodynamic data from the TVT registry are site-reported and not adjudicated via a core laboratory, the use of which has been shown to provide more reliable data (35) . As such, there is likely some interpretation variability in the reported echocardiographic and hemodynamic parameters.
Finally, it is likely that there were some confounding factors (e.g., frailty, pulmonary hypertension), that were not accounted for by our regression models. Values are median (interquartile range) or n (%). *Change from Baseline KCCQ-OS >20 points. †Refers to absolute change in KCCQ-OS. ‡Adjusted odds ratio. Tables 2 and 5 Effect of EF and Aortic Valve Gradient on TAVR Outcomes
CONCLUSIONS
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